Abaloparatide formulations and methods of testing, storing, modifying, and using same
Provided herein are newly discovered methods of analyzing abaloparatide samples for abaloparatide isomers. Additionally, methods of storing and treating with abaloparatide in view of the newly discovered abaloparatide isomers are described.
1. A method comprising:
providing a formulated abaloparatide drug product; and
analyzing the formulated abaloparatide drug product for the presence of beta-Asp10, wherein analyzing the formulated abaloparatide drug product for the presence of beta-Asp10 comprises using an HPLC and/or UPLC using a binary solvent system with a mobile phase comprising acetonitrile and an aqueous buffer comprising ammonium phosphate ((NH 4 )H 2 PO 4 ), wherein said aqueous buffer has a pH range of between 7.5-8.5 prior to mixing with any additional mobile phase solvent.
2. The method of claim 1 , wherein providing the formulated abaloparatide drug product comprises constituting an abaloparatide API into an aqueous formulation.
3. The method according to claim 1 , wherein analyzing the formulated abaloparatide drug product comprises detecting and quantifying the presence of beta-Asp10 in the formulated abaloparatide drug product.
4. The method according to claim 3 , comprising detecting and quantifying the presence of ≤3% w/w beta-Asp10 of a total peptide content in the formulated abaloparatide drug product.
5. The method according to claim 3 , comprising detecting and quantifying the presence of ≤1% w/w beta-Asp10 of a total peptide content in the formulated abaloparatide drug product.
6. The method according to claim 3 , comprising detecting and quantifying the presence of ≤0.5% w/w beta-Asp10 of a total peptide content in the formulated abaloparatide drug product.
7. The method according to claim 1 , wherein said formulated abaloparatide drug product has an abaloparatide concentration of between 1.8 mg/mL and 2.2 mg/mL and a pH from 4.5-5.5.
8. The method according to claim 1 , wherein the UPLC comprises a C4-Silicon based, reverse phase column comprising particles with an average mean particle diameter of less than 3.0 microns.
9. A method comprising:
providing a formulated abaloparatide drug product; and
analyzing the formulated abaloparatide drug product for the presence of beta-Asp10 using an HPLC and/or UPLC using a binary solvent system with a mobile phase comprising acetonitrile and an aqueous buffer comprising ammonium phosphate ((NH 4 )H 2 PO 4 ), wherein said aqueous buffer has a pH range of between 7.5-8.5 prior to mixing with any additional mobile phase solvent.
10. The method of claim 9 , wherein providing the formulated abaloparatide drug product comprises constituting an abaloparatide API into an aqueous formulation.
11. The method according to claim 9 , wherein analyzing the formulated abaloparatide drug product comprises detecting and quantifying the presence of beta-Asp10 in the formulated abaloparatide drug product.
12. The method according to claim 11 , comprising detecting and quantifying the presence of ≤3% w/w beta-Asp10 of a total peptide content in the formulated abaloparatide drug product.
13. The method according to claim 11 , comprising detecting and quantifying the presence of ≤1% w/w beta-Asp10 of a total peptide content in the formulated abaloparatide drug product.
14. The method according to claim 11 , comprising detecting and quantifying the presence of ≤0.5% w/w beta-Asp10 of a total peptide content in the formulated abaloparatide drug product.
15. The method according to claim 9 , wherein said formulated abaloparatide drug product has an abaloparatide concentration of between 1.8 mg/mL and 2.2 mg/mL and a pH from 4.5-5.5.
16. The method according to claim 9 , wherein the UPLC comprises a C4-Silicon based, reverse phase column comprising particles with an average mean particle diameter of less than 3.0 microns.
17. An abaloparatide drug product manufacturing process comprising:
providing a formulated abaloparatide drug product; and
analyzing the formulated abaloparatide drug product for the presence of beta-Asp10, wherein analyzing the formulated abaloparatide drug product for the presence of beta-Asp10 comprises using an HPLC and/or UPLC using a binary solvent system with a mobile phase comprising acetonitrile and an aqueous buffer comprising ammonium phosphate ((NH 4 )H 2 PO 4 ), wherein said aqueous buffer has a pH range of between 7.5-8.5 prior to mixing with any additional mobile phase solvent.
18. The manufacturing process of claim 17 , wherein providing the formulated abaloparatide drug product comprises constituting an abaloparatide API into an aqueous formulation.
19. The manufacturing process according to claim 17 , wherein analyzing the formulated abaloparatide drug product comprises detecting and quantifying the presence of beta-Asp10 in the formulated abaloparatide drug product.
20. The manufacturing process according to claim 19 , comprising detecting and quantifying the presence of ≤3% w/w beta-Asp10 of the total peptide content in the formulated abaloparatide drug product.
21. The manufacturing process according to claim 19 , comprising detecting and quantifying the presence of ≤1% w/w beta-Asp10 of the total peptide content in the formulated abaloparatide drug product.
22. The manufacturing process according to claim 19 , comprising detecting and quantifying the presence of ≤0.5% w/w beta-Asp10 of the total peptide content in the formulated abaloparatide drug product.
23. The manufacturing process according to claim 17 , wherein said formulated abaloparatide drug product has an abaloparatide concentration of between 1.8 mg/mL and 2.2 mg/mL and a pH from 4.5-5.5.
24. The manufacturing process according to claim 17 , wherein the UPLC comprises a C4-Silicon based, reverse phase column comprising particles with an average mean particle diameter of less than 3.0 microns.